References
- Oelkers W, Helmerhorst FM, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13
- Oelkers W, Foidart JM, Dombrovicz M, et al. Effects of a new oral contraceptive containing an anti-mineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21
- Brändle E, Gottwald E, Melzer H, et al. Influence of oral contraceptive agents on kidney function and protein metabolism. Eur J Clin Pharmacol 1992; 43: 643–6
- Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanonr`. Contraception 1998; 58: 109–15S
- Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34
- Crane MG, Harris JJ. Oral Contraceptives and High Blood Pressure. Gaineasville. Dolphin Press. 1974; 179: 159
- Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993; 47: 367–76
- Oelkers W. Effects of estrogen and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71
- Oelkers W, Berger V, Bolik A, et al. Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–42